Galileo Cosmos – a powerful tool in life science data exploration and analysis
In Life Sciences you have lots of data and you’re already answering lots of questions. What about the questions you’re not asking? Spending millions of dollars on data to answer specific questions leaves you with a lot of data and a lot of additional questions – Galileo Cosmos helps you find the critical additional questions and answers that will add value to your business.
Life sciences is all about patient flow – moving through treatment protocols for a specific disease, being managed from drug to drug to improve outcomes, managing new diseases as comorbidities develop.
Using conventional analytic approaches, conducting a patient flow analysis is cumbersome, time consuming and often confined by the constraints of the analysis. With Galileo Cosmos you can complete multiple patient flow analyses across large and small patient groups using different flow parameters – all in minutes instead of days.
The benefits of Galileo Cosmos in flow analysis:
- Speed – even with millions of patients a flow analysis will be completed in a few minutes
- Flexibility – testing flow characteristics using different competitive product sets is as easy as a drag-and-drop selection process
- Detailed output – all stages of flow are quantified by time as well as patient count
- Multiple cohorts – any number of different cohort definitions can be used so that you can test how these factors affect the flow results
Sophisticated patient flow is a core capability of Galileo Cosmos. Using EHR and/or claims data, Galileo Cosmos gives you the most powerful patient flow analysis available.
Better Targeting through Segmentation and Cohort Design
In Life Sciences we live and die by the reliability of our patient segmentation. Some call it cohort definition, but it is the same thing – a group of patients sharing similar characteristics that can be targeted for research or marketing purposes.
There are three types of patient cohort:
- Defined Cohort – based on known or expected characteristics, typically used in clinical trial design
- Behavioural cohort – based on characteristics that are expected such as response / non-response to drug therapy
- Discovered cohort – identified through data exploration not normally conducted using traditional methods
Conventional analytics continue to work extremely well at answering the first two cohort types. Galileo Cosmos is specifically designed to challenge the third – the discovered cohort. Multiple case studies have now demonstrated the value of Cosmos in identifying and quantifying these previously unknown cohorts, generating significant value in research, clinical trials and commercial settings.
Better understanding of the Complex Patient Journey
The days of managing patients as simple entities are over. We no longer consider single diseases but are forced to manage the reality that patients are very complex.
- Patients have multiple conditions and their treatment overlaps
- Patients are seen by different types of healthcare professional whose roles interact
- Patients are treated with multiple drugs and other therapies that must be tracked and measured
Patients are very complex and the data available to help us better understand them are also becoming more complex.
- Prescribing data is now joined by compliance and persistence data
- Diagnostic test data are now joined by population health statistics
- Individual data are now joined by the “omix” datasets
Traditional analytical tools are not well suited to the needs of this new set of complex patients, but Galileo Cosmos was designed to meet these needs. Among the capabilities of Cosmos that are relevant to the needs of the new more complex patient analysis are:
- Multi-source data combination for analysis
- Flexibility of approach with link analysis as well as statistics, combined with complex variable creation
- Comprehensive management of temporal elements in analysis
These features allow us to:
- define the characteristics of the complex patient
- identify details of the multi-channel management of the patients
- quantify opportunities for improved care, whether procedural or drug related
Galileo Cosmos opens the window on understanding complex patients.